{"protocolSection":{"identificationModule":{"nctId":"NCT00391274","orgStudyIdInfo":{"id":"10717"},"secondaryIdInfos":[{"id":"H3E-MC-JMID","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy"},"statusModule":{"statusVerifiedDate":"2011-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-10"},"primaryCompletionDateStruct":{"date":"2008-12","type":"ACTUAL"},"completionDateStruct":{"date":"2010-06","type":"ACTUAL"},"studyFirstSubmitDate":"2006-10-19","studyFirstSubmitQcDate":"2006-10-19","studyFirstPostDateStruct":{"date":"2006-10-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-12-21","resultsFirstSubmitQcDate":"2010-03-15","resultsFirstPostDateStruct":{"date":"2010-03-30","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-04-08","lastUpdatePostDateStruct":{"date":"2011-04-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":211,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed","type":"EXPERIMENTAL","interventionNames":["Drug: pemetrexed"]},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: docetaxel"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment","armGroupLabels":["Pemetrexed"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment","armGroupLabels":["Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival","description":"Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.","timeFrame":"baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)"}],"secondaryOutcomes":[{"measure":"Overall Tumor Response","description":"Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.","timeFrame":"baseline to measured tumor response (up to 24 months after study enrollment)"},{"measure":"Progression-Free Survival (PFS)","description":"Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.","timeFrame":"baseline to measured progressive disease (up to 24 months after study enrollment)"},{"measure":"Duration of Response","description":"Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as \"Number of Patients with Disease Progression\".","timeFrame":"time of response to progressive disease (up to 24 months)"},{"measure":"Pharmacology Toxicity","description":"Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.","timeFrame":"first dose of study drug up to 24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy\n* At least one prior chemotherapy for palliative therapy\n* Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\nExclusion Criteria:\n\n* Concurrent administration of any other tumor therapy\n* Pregnant or breast feeding\n* Serious concomitant disorders\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hangzhou","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanjing","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tianjin","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wuhan","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}}]},"referencesModule":{"references":[{"pmid":"24342300","type":"DERIVED","citation":"Wu YL, Sun Y, Zhou CC, Zhang L, Yu SY, Ma SL, Han LL, Zhang XQ, Orlando M. Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients. Chin Med J (Engl). 2013;126(24):4624-8."},{"pmid":"23182660","type":"DERIVED","citation":"Sun Y, Wu YL, Zhou CC, Zhang L, Zhang L, Liu XY, Yu SY, Jiang GL, Li K, Qin SK, Ma SL, Han L, Quinlivan M, Orlando M, Zhang XQ. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Lung Cancer. 2013 Feb;79(2):143-50. doi: 10.1016/j.lungcan.2012.10.015. Epub 2012 Nov 20."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"FG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"104"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"57"}]}],"dropWithdraws":[{"type":"Death Due to Study Disease","reasons":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"45"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death Due to Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death Due to Indeterminate Cause","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death Not Study Related","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"BG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"211"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.4","spread":"9.33"},{"groupId":"BG001","value":"55.9","spread":"11.41"},{"groupId":"BG002","value":"56.1","spread":"10.39"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"77"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"134"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"211"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"211"}]}]}]},{"title":"Basis for Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Cytological","categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"69"}]}]},{"title":"Histopathological","categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"142"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage IIIA - the cancer has spread to nearby tissue or spread to far away lymph nodes; Stage IIIB - cancer spread to opposite side of chest, more than one tumor within same lobe of lung; Stage IV - the cancer has spread to other organs of the body such as the other lung, brain, or liver.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]},{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"42"}]}]},{"title":"Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"165"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"27"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"161"}]}]},{"title":"2 - Ambulatory, No Work Activities","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"23"}]}]}]},{"title":"Number of Sites of Metastatic Disease","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"1 Site","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"25"}]}]},{"title":"2 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"63"}]}]},{"title":"3 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"64"}]}]},{"title":"4 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}]}]},{"title":"5 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]}]},{"title":"6 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"}]}]},{"title":"7 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]},{"title":"8 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"9 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"10 Sites","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"148"}]}]},{"title":"Carcinoma, Squamous Cell","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"52"}]}]},{"title":"Mixed Cell Carcinoma, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never Smoked","categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"99"}]}]},{"title":"Smoked, But Quit","categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"97"}]}]},{"title":"Currently Smoking","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"Overall Tumor Response","description":"Response based on Response Evaluation Criteria In Solid Tumors (RECIST), which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatments. CR (complete response) = disappearance of all target lesions; PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions; SD (stable disease) = small changes that do not meet above criteria.","populationDescription":"Patients who received at least one dose of study drug and qualified for tumor response analysis (met following criteria: histologic or cytologic diagnosis of NSCLC that was not amenable to curative therapy; no concurrent systemic chemotherapy; presence of measurable or evaluable disease).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline to measured tumor response (up to 24 months after study enrollment)","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"98"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"46"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"36"}]}]},{"title":"Early Death from Malignant Disease","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Early Death from Other Causes","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1326","pValueComment":"Logistic regression of best overall tumor response (complete response + partial response).","statisticalMethod":"Regression, Logistic","statisticalComment":"Treatment was the only covariate.","paramType":"Odds Ratio (OR)","paramValue":"2.50","ciPctValue":"95","ciLowerLimit":"0.76","ciUpperLimit":"8.25"}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"Progression-free survival (PFS) time was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause. For patients who were alive and had not progressed, PFS was censored at the last contact.","populationDescription":"Intent to treat population. Patient censored:\n\npemetrexed=25, docetaxel=39.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"baseline to measured progressive disease (up to 24 months after study enrollment)","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"104"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.8","upperLimit":"3.1"},{"groupId":"OG001","value":"3.1","lowerLimit":"2.8","upperLimit":"3.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7704","statisticalMethod":"Log Rank","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7784","statisticalMethod":"Regression, Cox","statisticalComment":"Treatment was the only covariate.","paramType":"Hazard Ratio (HR)","paramValue":"1.05","ciPctValue":"95","ciLowerLimit":"0.75","ciUpperLimit":"1.46"}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of tumor response is the duration from date of first objective status assessment of a complete or partial response to the first date of progression or death from any cause. For each patient who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, duration of tumor response was censored at the time of last prior contact. Due to the low number of patients in the analysis, the median duration of tumor response could not be calculated for the docetaxel arm. Available data are presented as \"Number of Patients with Disease Progression\".","populationDescription":"Patients who qualified for response (met following criteria: histologic or cytologic diagnosis of NSCLC that was not amenable to curative therapy; no concurrent systemic chemotherapy; presence of measurable or evaluable disease). Results not presented because median was not calculable for the docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"time of response to progressive disease (up to 24 months)","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Pharmacology Toxicity","description":"Maximum common terminology criteria (CTC) Grade 3 or 4 toxicities possibly related to study drug are reported. The worst grade event per cycle is reported. Grades range from 0 (none) to 5 (death). Grade 3 events are severe and Grade 4 events are life-threatening.","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"first dose of study drug up to 24 months","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"102"}]}],"classes":[{"title":"Serum Glutamic Pyruvic Transaminase","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hemoglobin","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}]},{"title":"Leukocytes","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"21"}]}]},{"title":"Lymphopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutrophils/Granulocytes","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"29"}]}]},{"title":"Platelets","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Anorexia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"Enteritis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Fatigue (Asthenia, Lethargy, Malaise)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]},{"title":"Febrile Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Infection (Clinical/Microbiological: Neutrophils)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Infection (Unknown: Pneumonia)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Mucositis/Stomatitis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neuropathy: Motor","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pain: Thorax Not Otherwise Specified (NOS)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pericardial Effusion (Non-Malignant)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pulmonary/Upper Respiratory - Other","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Rash/Desquamation","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up. An amendment allowed for the collection of overall survival on an additional 43 survival events. At the time the original record was released, it was not possible to provide results with the 95% Confidence Interval (CI) since the upper limit was not calculable. The median and 95% CIs are now reported.","populationDescription":"Intent to treat population. Number of patients censored (up to 24 months): pemetrexed = 51, docetaxel = 55. Number of participants censored (up to 30 months): pemetrexed = 30, docetaxel = 32.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"104"}]}],"classes":[{"title":"Overall Survival (up to 24 months)","categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"8.7","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."},{"groupId":"OG001","value":"12.2","lowerLimit":"9.1","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment."}]}]},{"title":"Overall Survival (up to 30 months)","categories":[{"measurements":[{"groupId":"OG000","value":"11.4","lowerLimit":"8.6","upperLimit":"13.4"},{"groupId":"OG001","value":"11.5","lowerLimit":"8.9","upperLimit":"15.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4921","pValueComment":"P-value for Overall Survival (up to 24 months)","statisticalMethod":"Regression, Cox","statisticalComment":"Treatment was the only covariate.","paramType":"Hazard Ratio (HR)","paramValue":"1.14","ciPctValue":"95","ciLowerLimit":"0.78","ciUpperLimit":"1.68"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9256","pValueComment":"P-value for Overall Survival (up to 30 months)","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"1.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.40"}]},{"type":"POST_HOC","title":"Number of Patients With Disease Progression","description":"Number of patients who have died or have had progression of disease. This outcome substitutes for the outcome on Duration of Response.","populationDescription":"Patients who qualified for response (met following criteria: histologic or cytologic diagnosis of NSCLC that was not amenable to curative therapy; no concurrent systemic chemotherapy; presence of measurable or evaluable disease). Patients censored: pemetrexed=6, docetaxel=3.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"time of response to progressive disease (up to 12 months)","groups":[{"id":"OG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment."},{"id":"OG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed","description":"500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment.","seriousNumAffected":10,"seriousNumAtRisk":106,"otherNumAffected":99,"otherNumAtRisk":106},{"id":"EG001","title":"Docetaxel","description":"75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment.","seriousNumAffected":12,"seriousNumAtRisk":102,"otherNumAffected":95,"otherNumAtRisk":102}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death in one pemetrexed patient.","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death in one docetaxel patient.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death in one docetaxel patient.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death in one docetaxel patient.","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":102}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":102}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":102}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":14,"numAffected":6,"numAtRisk":102}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":102}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":102}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":106},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":102}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":102}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":102}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":48,"numAtRisk":106},{"groupId":"EG001","numEvents":71,"numAffected":42,"numAtRisk":102}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":102}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":17,"numAtRisk":106},{"groupId":"EG001","numEvents":22,"numAffected":15,"numAtRisk":102}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":102}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":102}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":102}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":33,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":102}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":23,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":106},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":102}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":71,"numAffected":30,"numAtRisk":102}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":102}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":15,"numAtRisk":106},{"groupId":"EG001","numEvents":91,"numAffected":31,"numAtRisk":102}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":38,"numAtRisk":106},{"groupId":"EG001","numEvents":40,"numAffected":30,"numAtRisk":102}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":102}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":102}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":102}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":102}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":102}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":102}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":27,"numAtRisk":106},{"groupId":"EG001","numEvents":30,"numAffected":24,"numAtRisk":102}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":31,"numAtRisk":106},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":102}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":102}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":21,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":102}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The primary outcome measure of this trial was designed to include pooled data. In addition, the results for the outcome on Duration of Response could not be presented due to the low number of patients being analyzed in the docetaxel group."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}